EGFR and dysplasia: Nevertheless, the TBR of these tracers was less than 1.4 for NDBE and LGD and was less than 1.7 for both heptapeptides in HGD and esophageal adenocarcinoma, suggesting that targeting EGFR and ErbB2 may not provide optimal dysplasia or esophageal adenocarcinoma detection.